These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

430 related items for PubMed ID: 23042019

  • 1. Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience.
    Hamidieh AA, Alimoghaddam K, Jahani M, Bahar B, Mousavi SA, Iravani M, Behfar M, Jalali A, Jalili M, Hamdi A, Ghavamzadeh A.
    J Pediatr Hematol Oncol; 2013 Aug; 35(6):e239-45. PubMed ID: 23042019
    [Abstract] [Full Text] [Related]

  • 2. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
    Wang HH, Feng SZ, Wang M, Wei JL, Jiang EL, Zhang L, Huang Y, Zhou SY, Liu QG, Qiu LG, Han MZ, Yan WW.
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
    [Abstract] [Full Text] [Related]

  • 3. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
    Lee JW, Kang HJ, Kim S, Lee SH, Yu KS, Kim NH, Jang MK, Kim H, Song SH, Park JD, Park KD, Shin HY, Jang IJ, Ahn HS.
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Report From the Japanese Society for Hematopoietic Cell Transplantation.
    Ishida H, Kato M, Kudo K, Taga T, Tomizawa D, Miyamura T, Goto H, Inagaki J, Koh K, Terui K, Ogawa A, Kawano Y, Inoue M, Sawada A, Kato K, Atsuta Y, Yamashita T, Adachi S.
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2141-2147. PubMed ID: 26271192
    [Abstract] [Full Text] [Related]

  • 5. Impact of conditioning regimen in allogeneic hematopoetic stem cell transplantation for children with acute myelogenous leukemia beyond first complete remission: a pediatric blood and marrow transplant consortium (PBMTC) study.
    Sisler IY, Koehler E, Koyama T, Domm JA, Ryan R, Levine JE, Pulsipher MA, Haut PR, Schultz KR, Taylor DS, Frangoul HA.
    Biol Blood Marrow Transplant; 2009 Dec; 15(12):1620-7. PubMed ID: 19896086
    [Abstract] [Full Text] [Related]

  • 6. [A comparison of toxicity and efficacy between busulfan plus fludarabine and busulfan plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia].
    Liu H, Fan ZP, Jiang QL, Huang F, Zhou HS, Zhang X, Yu GP, Wu MQ, Sun J, Liu QF.
    Zhonghua Nei Ke Za Zhi; 2012 Nov; 51(11):880-4. PubMed ID: 23291027
    [Abstract] [Full Text] [Related]

  • 7. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
    Lu Y, Zhao YL, Zhang JP, Xiong M, Cao XY, Liu DY, Sun RJ, Wei ZJ, Zhou JR, Lu DP.
    Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
    [Abstract] [Full Text] [Related]

  • 8. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A, Iori A, Guglielmi C, Romano A, Cerretti R, Torromeo C, Micozzi A, Fenu S, Laurenti L, Donato V, De Felice L, Arcese W.
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [Abstract] [Full Text] [Related]

  • 9. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
    Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, Mohty M.
    J Clin Oncol; 2013 Oct 01; 31(28):3549-56. PubMed ID: 23980086
    [Abstract] [Full Text] [Related]

  • 11. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB, Coughlin E, Kennedy KF, Alyea EP, Armand P, Attar EC, Ballen KK, Cutler C, Dey BR, Koreth J, McAfee SL, Spitzer TR, Antin JH, Soiffer RJ, Ho VT.
    Biol Blood Marrow Transplant; 2013 Jun 01; 19(6):981-7. PubMed ID: 23562738
    [Abstract] [Full Text] [Related]

  • 12. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
    Guièze R, Cornillet-Lefebvre P, Lioure B, Blanchet O, Pigneux A, Recher C, Bonmati C, Fegueux N, Bulabois CE, Bouscary D, Vey N, Delain M, Turlure P, Himberlin C, Harousseau JL, Dreyfus F, Béné MC, Ifrah N, Chevallier P, GOELAMS.
    Am J Hematol; 2012 Dec 01; 87(12):1052-6. PubMed ID: 22911473
    [Abstract] [Full Text] [Related]

  • 13. Survival after second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.
    Meshinchi S, Leisenring WM, Carpenter PA, Woolfrey AE, Sievers EL, Radich JP, Sanders JE.
    Biol Blood Marrow Transplant; 2003 Nov 01; 9(11):706-13. PubMed ID: 14652854
    [Abstract] [Full Text] [Related]

  • 14. The outcome of allogeneic hematopoietic stem cell transplants without total body irradiation in pediatric patients with acute lymphoblastic leukemia: single centre experience.
    Hamidieh A, Kargar M, Jahani M, Alimoghaddam K, Bahar B, Mousavi SA, Iravani M, Jalali A, Jalili M, Ghavamzadeh A.
    J Pediatr Hematol Oncol; 2012 Mar 01; 34(2):101-7. PubMed ID: 22367385
    [Abstract] [Full Text] [Related]

  • 15. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
    Liu QF, Sun J, Xu D, Zhang Y, Fan ZP, Wei YQ, Meng FY, Zhou SY.
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct 01; 24(10):1117-9. PubMed ID: 15485779
    [Abstract] [Full Text] [Related]

  • 16. Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan.
    Sakaguchi H, Muramatsu H, Hasegawa D, Kudo K, Ishida H, Yoshida N, Koh K, Noguchi M, Shiba N, Tokimasa S, Fukuda T, Goto H, Miyamura T, Nakazawa Y, Hashii Y, Inoue M, Atsuta Y, Pediatric AML Working Group of the Japan Society for Hematopoietic Cell Transplantation.
    Pediatr Blood Cancer; 2019 Jan 01; 66(1):e27459. PubMed ID: 30270523
    [Abstract] [Full Text] [Related]

  • 17. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H, Al-Shammari Z, Al-Ghonaium A, Al-Dhekri H, Al-Muhsen S, Al-Saud B, Arnaout R, Al-Seraihy A, Al-Jefri A, Al-Ahmari A, Ayas M, El-Solh H.
    Biol Blood Marrow Transplant; 2010 Jun 01; 16(6):818-23. PubMed ID: 20079864
    [Abstract] [Full Text] [Related]

  • 18. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S.
    Biol Blood Marrow Transplant; 2008 Jun 01; 14(6):651-7. PubMed ID: 18489990
    [Abstract] [Full Text] [Related]

  • 19. Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: A study from the pediatric ALL working group of the Japan Society for Hematopoietic Cell Transplantation.
    Kato M, Ishida H, Koh K, Inagaki J, Kato K, Goto H, Kaneko T, Cho Y, Hashii Y, Kurosawa H, Takita J, Hamamoto K, Inoue M, Sawada A, Suzuki R, Kato K.
    Pediatr Blood Cancer; 2015 Oct 01; 62(10):1844-50. PubMed ID: 26053959
    [Abstract] [Full Text] [Related]

  • 20. Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.
    Liu QF, Fan ZP, Wu MQ, Sun J, Wu XL, Xu D, Jiang QL, Zhang Y, Huang F, Wei YQ, Zhao J, Yu GP, Meng FY.
    Ann Hematol; 2013 May 01; 92(5):679-87. PubMed ID: 23274355
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.